AI
| Followers | 1084 |
| Posts | 142881 |
| Boards Moderated | 5 |
| Alias Born | 01/25/2009 |
Friday, February 27, 2015 9:55:27 AM
$BICX Highlights
*Increase in recent main stream media exposure - Naltrexone was recently covered in Time Magazine and The New York Times.
*BioCorRx and/or its Start Fresh Program was recently featured on The Doctors, Bloomberg, Fox Business News, and in multiple local news segments in Los Angeles, San Francisco, San Diego, New York and others. Many of those can be seen on the company’s website, Facebook page or YouTube channel.
*“By focusing on branding and expansion to reach mass market adoption, BioCorRx Inc. will continue to position its Start Fresh Program as a leader in treating alcohol and opioid addiction,” stated Lourdes Felix.
*Company became cash flow positive in 2014 for the first time in its history due to increase in license fees, royalties and direct sales.
*Currently 12 clinics in the US using the program compared to only one in late 2013 with more scheduled to go online in 2015.
*Under current LOI to acquire other formulas from Trinity Rx Solutions including the naltrexone formula to expand product base and bring down costs.
*Tight float: BICX completed a large buyback and retirement in 2012 of 27 million shares and retirement of outstanding common stock.
*Excellent team. Experienced veterans added including John Ohanesian, formerly CEO and President of Bosley Inc.
*BioCorRx, Inc. has the worldwide rights (except in Australia and New Zealand) to a highly effective, proprietary implant formulation of the FDA-approved drug, Naltrexone.
*Vast US Market: Some studies report that 10-20 million people in the US have a drinking problem and the cost of alcoholism to society can top $100-200 billion annually.
*Rare combination of tremendous profit potential and dramatic positive social impact for millions of Americans and all those who are affected by the evils of alcohol addiction.
*Number of patients treated up over 400% from 2013 to 2014.
*Eliminated all convertible debt in 2014.
*Increase in recent main stream media exposure - Naltrexone was recently covered in Time Magazine and The New York Times.
*BioCorRx and/or its Start Fresh Program was recently featured on The Doctors, Bloomberg, Fox Business News, and in multiple local news segments in Los Angeles, San Francisco, San Diego, New York and others. Many of those can be seen on the company’s website, Facebook page or YouTube channel.
*“By focusing on branding and expansion to reach mass market adoption, BioCorRx Inc. will continue to position its Start Fresh Program as a leader in treating alcohol and opioid addiction,” stated Lourdes Felix.
*Company became cash flow positive in 2014 for the first time in its history due to increase in license fees, royalties and direct sales.
*Currently 12 clinics in the US using the program compared to only one in late 2013 with more scheduled to go online in 2015.
*Under current LOI to acquire other formulas from Trinity Rx Solutions including the naltrexone formula to expand product base and bring down costs.
*Tight float: BICX completed a large buyback and retirement in 2012 of 27 million shares and retirement of outstanding common stock.
*Excellent team. Experienced veterans added including John Ohanesian, formerly CEO and President of Bosley Inc.
*BioCorRx, Inc. has the worldwide rights (except in Australia and New Zealand) to a highly effective, proprietary implant formulation of the FDA-approved drug, Naltrexone.
*Vast US Market: Some studies report that 10-20 million people in the US have a drinking problem and the cost of alcoholism to society can top $100-200 billion annually.
*Rare combination of tremendous profit potential and dramatic positive social impact for millions of Americans and all those who are affected by the evils of alcohol addiction.
*Number of patients treated up over 400% from 2013 to 2014.
*Eliminated all convertible debt in 2014.
Visit my board"NY Penny Stock Exchange" for today's pick at http://investorshub.advfn.com/boards/board.aspx?board_id=16752
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
